The Spanish pharma sector sees a massive new contract worth €70 million

An impressive contract was signed in the Castilian-Leonese health system. The Government presided by Alfonso Fernández Mañueco has resolved a $79 million (€70 million) tender to provide hospitals and health centers in the public regional network with injectable and tablet medicines, as can be seen from the profile of the regional contractor.

The contract in question is expected to last one year and is divided into 23 different lots, which have been awarded to different pharmaceutical companies. Among the winners and those who have won a large part of the contract are Janssen, Merck, Novartis and Roche. The centers to which these drugs are directed are the Complejo Asistencial de Ávila, the Complejo Asistencial de Burgos, the Hospital Santiago Apóstol de Miranda de Ebro, the Hospital Santos Reyes de Aranda de Duero and the Hospital Clínico Universitario de Valladolid, among others.

Find out more details about the massive contract resolved by the Government to the health sector in Spain and be the first to find the most important business news with our companion app, Born2Invest.

Janssen will supply its Ustekinumab product, indicated for the treatment of adult patients with ulcerative colitis

The largest amount corresponds to the Johnson&Johnson group’s pharmacist, Janssen, which will supply its Ustekinumab product, indicated for the treatment of adult patients with ulcerative colitis, for a total of $13.2 million (€11.7 million).

The company will also provide hospitals in Castilla y León with Etravirina, an antiviral drug used for the treatment of infection caused by the human immunodeficiency virus (HIV), the agent that causes AIDS, and will do so for more than $452,000 (€400,000).

Novartis is also one of the big winners of this competition

The Swiss multinational has been awarded the supply of Fingolimod, an immunomodulator used in the treatment of multiple sclerosis, for $9.2 million (€8.2 million). This company has also been awarded another lot, for $7.1 million (€6.3 million), for the distribution of Ranibizumab, also known as Lucentis. That is a pharmacological therapy approved to improve vision and quality of life in patients with visual impairment due to diabetic macular edema (DME).

Novartis will also provide the Castilla y León Health Service (Sacyl) with a total of $3.4 million (€3 million) for its drug Nilotinib, a small molecule of the tyrosine kinase inhibitor that is approved for treating chronic myelogenous leukaemia.

The only company of Spanish origin that is involved in this contract is PharmaMar

Merck has also been selected. The pharmaceutical company will provide hospitals in the Cetuximab region with over $3.4 million (€3 million). This drug is used to treat colon cancer and other types of squamous cell cancer that affect the head and neck, such as some tumors of the mouth or larynx. It is applied weekly and is given intravenously.

In addition to these multinational pharmaceutical companies, this contract also includes Biogen España, Japan’s Takeda and Spain’s PharmaMar. PharmaMar will supply Yondelis (trabectedin), a marine-based antitumor compound, for $1.7 million (€1.5 million).

__

(Featured image by TBIT via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.